


PHARMACEUTICAL 2019



Matinas BioPharma Holdings Inc. Rank 162 of 363







PHARMACEUTICAL 2019



Matinas BioPharma Holdings Inc. Rank 162 of 363

The relative strengths and weaknesses of Matinas BioPharma Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Matinas BioPharma Holdings Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 27% points. The greatest weakness of Matinas BioPharma Holdings Inc. is the variable Net Income, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 78% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	13,085
Cost of Goods Sold	0
Intangible Assets	1,336
Liabilities, Current	2,840
Liabilities, Non-Current	962
Other Assets	3,478
Other Compr. Net Income	0
Other Expenses	-507
Other Liabilities	0
Other Net Income	57
Other Revenues	120
Property and Equipment	2,043
Research and Development	6,787
Selling, General and Administrative Expense	7,979

Output Variable	Value in 1000 USD
Assets	19,943
Liabilities	3,802
Expenses	14,259
Revenues	120
Stockholders Equity	16,142
Net Income	-14,083
Comprehensive Net Income	-14,083
Economic Capital Ratio	115%

